Prediabetes affects approximately 96 million adults in the United States, about 38% of the adult population, and approximately 70-80% of people with prediabetes will eventually develop type 2 diabetes without intervention. GLP-1 receptor agonists have demonstrated the ability to reverse or delay this progression, primarily through weight loss and improved insulin sensitivity, though they are not currently FDA-approved specifically for prediabetes prevention.

How GLP-1 Medications Affect Glucose Metabolism

GLP-1 receptor agonists improve glucose metabolism through three mechanisms beyond weight loss:

Glucose-dependent insulin secretion: GLP-1 receptor activation stimulates the pancreas to release insulin when blood glucose is elevated. This mechanism is present only when glucose is high, which is why GLP-1 medications carry low hypoglycemia risk. In people with prediabetes, whose beta cell function is not yet severely impaired, this augmented insulin response helps control post-meal glucose spikes.

Glucagon suppression: GLP-1 receptor activation reduces glucagon secretion from the pancreas. Glucagon raises blood glucose by stimulating the liver to release stored glycogen. Suppressing glucagon in prediabetes reduces hepatic glucose output between meals.

Gastric emptying delay: Slowing how quickly food reaches the small intestine spreads glucose absorption over a longer time, reducing post-meal glucose peaks.

Together with weight loss, which reduces insulin resistance and increases cellular glucose uptake, these mechanisms produce meaningful reductions in fasting and post-meal glucose in people with prediabetes.

What the STEP-1 and SURMOUNT-1 Trials Showed for Prediabetes

The STEP and SURMOUNT trials did not enroll people with established diabetes but did include participants with prediabetes at baseline. In STEP-1, approximately 20% of participants had prediabetes. Among those participants on semaglutide:

  • Fasting glucose normalized to non-diabetic range in the majority
  • HbA1c fell below the prediabetes threshold (6.5%) in most participants
  • At 68 weeks, significantly fewer semaglutide participants had progressed to diabetes compared to placebo

The SURMOUNT-1 trial with tirzepatide showed even more dramatic effects on glucose, by week 72, 95% of participants with prediabetes at baseline who were in the tirzepatide groups had normalized glucose to below the prediabetes threshold, compared to approximately 61% in the placebo group.

These are secondary analyses from weight loss trials, not primary diabetes prevention trials, but the magnitude of glucose normalization is striking.

What About Metformin and Lifestyle?

The Diabetes Prevention Program (DPP), a landmark NIH trial, established that lifestyle intervention (diet and exercise targeting 5-7% weight loss) reduced diabetes progression by 58%, and metformin reduced it by 31%, compared to placebo. These remain the first-line interventions for prediabetes.

GLP-1 medications appear to produce larger glucose improvements than either lifestyle intervention or metformin in head-to-head terms, though no trial has directly compared GLP-1 therapy to intensive lifestyle intervention in a prediabetes-specific population.

The clinical positioning is likely that GLP-1 medications are an option for prediabetic individuals who:

  • Cannot achieve sufficient weight loss through lifestyle modification alone
  • Have a BMI qualifying for GLP-1 prescribing under current indications
  • Have elevated cardiovascular risk that makes early diabetes prevention particularly important

Insurance Coverage for Prediabetes

This is where the current regulatory situation creates a gap. GLP-1 medications are not FDA-approved for prediabetes specifically. Coverage under the weight loss indication (Wegovy) requires a BMI of 30+ or 27+ with a weight-related comorbidity. Prediabetes qualifies as a comorbidity in many insurance policies, which makes the weight management indication the operative coverage pathway for eligible patients.

For patients who qualify under the weight management indication, addressing prediabetes is a clinical benefit that comes alongside weight loss, it does not require a separate indication.

For the weight management evidence, see What Is Semaglutide and How Does It Work for Weight Loss?. For the cost of accessing these medications, see How Much Does Semaglutide Cost Without Insurance?.